Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present AxoGen, Inc. (NASDAQ: AXGN).

Full DD Report for AXGN

You must become a subscriber to view this report.


Recent News from (NASDAQ: AXGN)

AxoGen to Host Third Annual Analyst and Investor Day on November 19, 2018
ALACHUA, Fla., Nov. 06, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that it will host its Third Annual Analyst and Investor Day on Monday, ...
Source: GlobeNewswire
Date: November, 06 2018 07:00
AxoGen's (AXGN) CEO Karen Zaderej on Q3 2018 Results - Earnings Call Transcript
AxoGen, Inc. (AXGN) Q3 2018 Earnings Conference Call October 29, 2018 4:30 PM ET Executives Kaila Krum – Vice President-Investor Relations and Corporate Development Karen Zaderej – Chairman, President and Chief Executive Officer Pete Mariani – Chief Financial...
Source: SeekingAlpha
Date: October, 29 2018 21:05
AxoGen beats by $0.06, beats on revenue
AxoGen (NASDAQ: AXGN ): Q3 Non-GAAP EPS of -$0.05 beats by $0.06 ; GAAP EPS of -$0.11 in-line. More news on: AxoGen, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: October, 29 2018 16:03
AxoGen, Inc. Reports 2018 Third Quarter Financial Results
Q3 Revenue of $22.7 million, representing 41% growth over prior year;  Management reiterates full year 2018 guidance and introduces 2019 guidance ALACHUA, Fla., Oct. 29, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovati...
Source: GlobeNewswire
Date: October, 29 2018 16:01
Avance® Nerve Graft Receives Regenerative Medicine Advanced Therapy (RMAT) Designation
RMAT Designation reinforces clinical significance of RANGER® registry data and acknowledges the unmet need for improved nerve repair solutions ALACHUA, Fla., Oct. 29, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surg...
Source: GlobeNewswire
Date: October, 29 2018 16:00
AxoGen to Participate at 73rd Annual American Society for Surgery of the Hand Meeting
Outcomes data for more than 400 nerve repairs with Avance ® Nerve Graft will be reviewed at hosted symposium Data will highlight outcomes on sensory, mixed, motor, and long gap nerve repairs ALACHUA, Fla., Sept. 07, 2018 (GLOBE NEWSWIRE) --   AxoGen, Inc. (NASDAQ: AXG...
Source: GlobeNewswire
Date: September, 07 2018 07:00
AxoGen, Inc. Appoints Angelo G. Scopelianos, Ph.D. as Vice President, Research and Development
ALACHUA, Fla., Sept. 04, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced the appointment of Angelo G. Scopelianos, Ph.D., to the newly created po...
Source: GlobeNewswire
Date: September, 04 2018 07:00
AxoGen, Inc. to Present at the Morgan Stanley Global Healthcare Conference
ALACHUA, Fla., Aug. 28, 2018 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today announced that Peter J. Mariani, chief financial officer, will present at the 16 th Annual Morgan Stanley Glo...
Source: GlobeNewswire
Date: August, 28 2018 07:00
Research Report Identifies Blucora, Sapiens International Corporation N.V, AxoGen, Epizyme, Nova Measuring Instruments, and Silver Standard Resources with Renewed Outlook - Fundamental Analysis, Calculating Forward Movement
NEW YORK, Aug. 20, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Blucora, Inc. (NASDAQ:BCOR), Sapiens International Corporation N.V. (NASD...
Source: GlobeNewswire
Date: August, 20 2018 07:30
Taking Another Look At AxoGen After A Nasty Post-Earnings Tumble
With great multiples come great expectations, and institutional growth investors can be merciless and indiscriminate in selling out of high-multiple growth stocks that don’t quite live up to expectations (or produce beat-and-raise quarters). This was one of my biggest concerns with A...
Source: SeekingAlpha
Date: August, 17 2018 05:33

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0843.4541.0543.8040.35575,837
2018-05-1744.0042.4544.400342.30362,563
2017-06-2015.1515.2515.6515.133132,876
2017-06-1914.7515.1515.2014.70164,562
2017-06-1614.5514.7514.8514.25222,858

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1122,36437,52359.6008Short
2018-12-1034,17883,48940.9371Short
2018-12-0771,181129,64854.9033Short
2018-12-0662,23790,48768.7800Short
2018-12-0447,44184,34356.2477Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AXGN.


About AxoGen, Inc. (NASDAQ: AXGN)

Logo for AxoGen, Inc. (NASDAQ: AXGN)

AxoGen OTCBB: AXGN is a leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. AxoGen s products offer a full suite of surgical nerve reconstruction solutions including Avance Nerve Graft, the only commercially available processed nerve allograft for bridging severed nerves, AxoGuard Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue.

 

 

 

Current Management

  • Karen Zaderej / CEO
  • Gregory G. Freitag / CFO, General Counsel
  • Jamie M. Grooms / Chairman
  • Gregory G. Freitag /
  • John Harper /
  • Mark Gold M.D. /
  • Joe Mandato /
  • John McLaughlin /
  • Robert J. Rudelius /
  • Karen Zaderej /

Current Share Structure

  • Market Cap: $1,538,145,370 - 05/14/2018
  • Authorized: 50,000,000 - 12/15/2012
  • Issue and Outstanding: 34,681,970 - 04/27/2018

 


Recent Filings from (NASDAQ: AXGN)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 14 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: May, 10 2018
Automatic shelf registration statement of securities of well-known seasoned issuers
Filing Type: S-3ASRFiling Source: edgar
Filing Date: May, 07 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: May, 07 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 13 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: March, 30 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: March, 30 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: March, 30 2018

 

 


Daily Technical Chart for (NASDAQ: AXGN)

Daily Technical Chart for (NASDAQ: AXGN)


Stay tuned for daily updates and more on (NASDAQ: AXGN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: AXGN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AXGN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of AXGN and does not buy, sell, or trade any shares of AXGN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/